|
rdfs:label
|
"Bevacizumab"@de
"Bevacizumab"@es
"Bevacizumab"@it
"Bevacizumab"@sh
"Bevacizumab"@sr-el
"Bevacizumab"@vi
"Bevasizumab"@id
"Bevasizumab"@tr
"Bevatsisumaab"@et
"bevacizumab"@ca
"bevacizumab"@cs
"bevacizumab"@en
"bevacizumab"@fr
"bevacizumab"@hr
"bevacizumab"@nb
"bevacizumab"@nl
"bevacizumab"@nn
"bevacizumab"@pt
"bevacizumab"@sl
"bevacizumab"@sv
"bevacizumab"@ro
"bevasitsumabi"@fi
"bewacizumab"@pl
"βεβασιζουμάμπη"@el
"Бевацизумаб"@sr-ec
"бевацизумаб"@ru
"бевацизумаб"@sr
"бевацизумаб"@uk
"Բևացիզումաբ"@hy
"אווסטין"@he
"بواسیزامب"@azb
"بواسیزامب"@fa
"بيفاسيزوماب"@ar
"बेवाकिज़ुमैब"@hi
"বেভাসিজুমাব"@bn
"ବେଭାସିଜୁମାବ"@or
"เบวะซิซิวแมบ"@th
"ベバシズマブ"@ja
"貝伐珠單抗"@zh-hant
"贝伐珠单抗"@zh
"贝伐珠单抗"@zh-cn
"贝伐珠单抗"@zh-hans
"베바시주맙"@ko
|
|
skos:altLabel
|
"12-IGG1"@en
"Altuzan"@tr
"Avastin"@pt
"Avastin"@sh
"Avastin"@sl
"Avastin"@sr
"Avastin"@en
"Avastin"@de
"Avastin"@es
"Avastin"@fi
"Bevacizumab"@pt
"Bevacizumabe"@pt
"R-435"@en
"RG-435"@en
"Rhumab-VEGF"@en
"antiVEGF"@en
"avastin"@hr
"bevakizumab"@nn
"μπεβασιζουμάμπη"@el
"Авастин"@ru
"בווציזומאב"@he
"ଆଭାଷ୍ଟିନ"@or
"アバスチン"@ja
"ベバシツマブ"@ja
"ベヴァシズマブ"@ja
"安维汀®"@zh
"癌思停®"@zh
"达攸同®"@zh
|
|
schema:description
|
"Thuốc y dược"@vi
"cheemesch Verbindung"@lb
"chemical compound"@en-ca
"chemical compound"@en-gb
"chemická sloučenina"@cs
"chemická zlúčenina"@sk
"chemiese verbinding"@af
"chemische Verbindung"@de-ch
"chemische verbinding"@nl
"component quimic"@oc
"compositum chemicum"@la
"compost químic"@ca
"composto químico"@gl
"composto químico"@pt-br
"compuesto quimico"@an
"compuesto químico"@es
"compuestu químicu"@ast
"compus chimic"@ro
"farmaco"@it
"farmasötik ilaç"@tr
"kemia kombinaĵo"@eo
"kemiallinen yhdiste"@fi
"kemisk forbindelse"@da
"kjemisk forbindelse"@nb
"kjemisk sambinding"@nn
"konposatu kimiko"@eu
"medicamento"@pt
"monoklonaler Antikörper, Protein, Arzneimittel"@de
"pharmaceutical drug"@en
"proteinë"@sq
"protéine"@fr
"senyawa kimia"@id
"związek chemiczny"@pl
"ķīmisks savienojums"@lv
"φάρμακο"@el
"քիմիական միացություն"@hy
"תרכובת"@he
"مركب كيميائي"@ar
"کیٖمیٲیی مُرَکَب"@ks
"औषधीय औषधि"@hi
"ফার্মাসিউটিক্যাল ড্রাগ"@bn
"分子標的治療薬の一つ"@ja
"药物"@zh
"수많은 유형의 암과 특정 눈병을 치료하기 위해 사용되는 약물"@ko
|
|
schema:dateModified
|
"2026-11-04T17:27:12+00:00"^^xsd:dateTime
|
|
schema:version
|
2564772932
|
|
wikibase:identifiers
|
36
|
|
wikibase:sitelinks
|
32
|
|
wikibase:statements
|
83
|
|
p:P10245
|
wd:statement/Q413299-07ebe740-4559-f8e6-a973-9cd60fb4b4ab
|
|
p:P10283
|
wd:statement/Q413299-CE402A8B-944A-487F-AFC9-DC9BC504F151
|
|
p:P10376
|
wd:statement/Q413299-18E3190A-4774-4D81-AE7F-F8431A5D5482
|
|
wd:statement/Q413299-19DD2D68-5769-4E2E-B049-316D97C55BA8
|
|
wd:statement/Q413299-2AC35C50-2E5C-4708-9D7F-C966934BBE42
|
|
wd:statement/Q413299-7B1C45AE-44F8-4F44-A7DD-38CDF3B7E5D9
|
|
wd:statement/Q413299-D0826CB3-DF50-463B-A00A-2FF889FC4BFD
|
|
wd:statement/Q413299-D55BE695-7CF6-4DA5-B088-D25276BFA890
|
|
p:P11143
|
wd:statement/Q413299-46D1275D-261E-4F20-9CEB-896D9DC87924
|
|
p:P1417
|
wd:statement/Q413299-21798964-CB34-4276-AE6D-6E49D636A84D
|
|
p:P2062
|
wd:statement/Q413299-EDACF729-18EC-4201-8675-B4C2C706179E
|
|
p:P2067
|
wd:statement/Q413299-c200ca3f-42cc-c30b-5167-a0f4174354fc
|
|
p:P2115
|
wd:statement/Q413299-3384F5B4-B57F-415F-83C8-163F0F9991F7
|
|
p:P2175
|
wd:statement/Q413299-038D4296-3CD7-4D5D-BACA-430235035BE2
|
|
wd:statement/Q413299-11CBF5C9-7534-424B-BB24-8E4CBD2148B1
|
|
wd:statement/Q413299-2309DCE2-660A-44C2-A703-4982C1DE108E
|
|
wd:statement/Q413299-2E357056-982E-4E0B-BF13-9A53B30CF687
|
|
wd:statement/Q413299-2E39A069-59A2-488F-8FA2-2718B1FD5B8B
|
|
wd:statement/Q413299-312BBA4A-C8FB-446B-A0C9-6789116C464A
|
|
wd:statement/Q413299-3405DF08-D475-4E02-A241-1C4A27F3C77A
|
|
wd:statement/Q413299-472AFDDB-CA35-4830-9E29-334C474AC9A8
|
|
wd:statement/Q413299-4E4EDB8B-5D3E-4B02-8575-34F6C2E0E373
|
|
wd:statement/Q413299-4FFA64D3-FC24-442F-8DF2-5F39E15F6C90
|
|
wd:statement/Q413299-5D8BDACD-728D-4B67-B617-78EB2EF98098
|
|
wd:statement/Q413299-6CA9728C-62C2-495B-A671-8CA4E32CAD64
|
|
wd:statement/Q413299-6D99168A-7CAE-45FE-ACA5-6EB3BEE31E3D
|
|
wd:statement/Q413299-7724AECB-C1DF-4DDD-B7AB-37364A28AD91
|
|
wd:statement/Q413299-7834A635-7047-4224-9339-5F21B92C1120
|
|
wd:statement/Q413299-7A1EA8DF-0896-4CC7-B7BF-F8499149CC22
|
|
wd:statement/Q413299-7D695471-585B-4D08-BCA2-F3CD4F014D1A
|
|
wd:statement/Q413299-87FE461B-89B0-42E8-93DC-115B1DC997F5
|
|
wd:statement/Q413299-90D0CE0F-37E6-483B-8A09-EE6972B4ED22
|
|
wd:statement/Q413299-96C37203-86D8-489B-B4BF-7E6360353469
|
|
wd:statement/Q413299-AA7FD32D-35FC-4377-B8F0-2285A9A3F046
|
|
wd:statement/Q413299-AE18CB52-9E8A-472D-B714-002FD433D6F7
|
|
wd:statement/Q413299-B70C40A0-6160-4563-A975-77C324C4AC75
|
|
wd:statement/Q413299-C12C91FC-3261-4D56-A063-BADBAAC40B3B
|
|
wd:statement/Q413299-C212E41F-1DB6-4815-B691-E13248539F6D
|
|
wd:statement/Q413299-C803BAD7-75B4-42BE-84DB-57BF7340DAC6
|
|
wd:statement/Q413299-CFF87F11-E4F6-409E-8D5D-B81735E363B2
|
|
wd:statement/Q413299-DB717C7F-74EC-4160-AF56-5AFA1105033D
|
|
wd:statement/Q413299-ED5047AB-F913-46A8-98E5-46F5DF127A2B
|
|
wd:statement/Q413299-EE895596-BDD2-4CA9-8A77-8FA7F1FC9163
|
|
wd:statement/Q413299-f21b9154-4dad-8397-47f1-53cefa708cbe
|
|
p:P2275
|
wd:statement/Q413299-6EB4B3F3-CDB5-4C28-9661-6785AFF74847
|
|
p:P231
|
wd:statement/Q413299-53C88FC5-CE53-4B23-88AC-9ADE1C1332CC
|
|
p:P2347
|
wd:statement/Q413299-31F8F94E-CB4B-422C-AF82-5C9570458776
|
|
p:P267
|
wd:statement/Q413299-C30DE4D4-C41C-4324-AF36-8069559F6D59
|
|
p:P274
|
wd:statement/Q413299-c83d1e08-47f0-33c3-3e78-0c357c32cb95
|
|
p:P279
|
wd:statement/Q413299-7EC58568-8CA2-40A4-83E7-695052969705
|
|
p:P2868
|
wd:statement/Q413299-3155CB90-37EB-4C25-987F-CF5287562F6B
|
|
wd:statement/Q413299-36AE8EF0-69B1-4895-9474-8C11A99214C5
|
|
wd:statement/Q413299-60CE64B3-0AE5-49EB-83D6-E2336D0150E5
|
|
wd:statement/Q413299-6551C3A8-F82F-4D0B-8637-0FED18C72901
|
|
wd:statement/Q413299-DBABFE45-4261-4CE3-9D71-C4DAFB43EA97
|
|
wd:statement/Q413299-F223A031-8B03-48A8-B30F-6EC0D16D5F95
|
|
p:P2892
|
wd:statement/Q413299-AC47EE7E-15DF-4ABB-A64E-52045D5C9320
|
|
p:P31
|
wd:statement/Q413299-554D8A8E-8963-4988-BC5F-E7E2BCD6EAB4
|
|
p:P3221
|
wd:statement/Q413299-1F1982ED-7E58-48EA-8BC3-B8D4AFB02592
|
|
p:P3345
|
wd:statement/Q413299-4F8F87C1-0437-455F-9980-F023815F4209
|
|
p:P3417
|
wd:statement/Q413299-AF7D4EAB-4303-4BE2-8E58-E8CC1268D6AF
|
|
p:P3489
|
wd:statement/Q413299-BCE9BFFC-E31D-49DF-878E-29BEA9E6AB91
|
|
p:P366
|
wd:statement/Q413299-9A618EFE-EA60-451D-88DD-0876D7E90050
|
|
wd:statement/Q413299-BDF31449-A984-4C36-8705-3617127A3BCD
|
|
p:P373
|
wd:statement/Q413299-479E5DB2-8B8B-433D-BE40-87171F41DCDE
|
|
p:P3780
|
wd:statement/Q413299-352FC030-B361-4CC3-A409-8B6D5F48A7B8
|
|
p:P4235
|
wd:statement/Q413299-20DF6672-D543-4EE7-8245-491795ABA85C
|
|
p:P4527
|
wd:statement/Q413299-FE8E2485-1789-45A1-ABAF-BBAF26FCA23C
|
|
p:P486
|
wd:statement/Q413299-9AEB8392-782A-4531-ABDF-3F5CC8E02603
|
|
p:P592
|
wd:statement/Q413299-1ECD54C4-CE58-4D80-9539-12A5D13963D5
|
|
p:P595
|
wd:statement/Q413299-45be9765-4f1d-c879-62ad-474d732bb913
|
|
p:P6366
|
wd:statement/Q413299-169B09DA-E890-4F6A-AC1A-255303615E02
|
|
wd:statement/Q413299-F43AEF9B-7854-4A19-AE15-47196F1F442C
|
|
p:P646
|
wd:statement/Q413299-A9607143-2EE7-4EA8-A72D-C30456271331
|
|
p:P652
|
wd:statement/Q413299-31C24381-D2C0-4693-B120-55419C79BE42
|
|
p:P665
|
wd:statement/Q413299-CD3C0AD2-3CF5-4FD9-BABF-AB13910DA87E
|
|
p:P672
|
wd:statement/Q413299-2baf8423-4cdd-9df9-f2f7-034c141895da
|
|
wd:statement/Q413299-9cbcf6b4-4348-ea8b-b5e0-127bd78e0a3b
|
|
wd:statement/Q413299-efa6b2c1-477a-b770-179c-66f1e12aaa01
|
|
p:P715
|
wd:statement/Q413299-EF2DF423-D0AC-4BCC-B35E-A47DCD86134B
|
|
p:P7524
|
wd:statement/Q413299-09F6B9E5-3072-406C-AF90-232EF4FBB5F1
|
|
p:P9272
|
wd:statement/Q413299-3699B8CE-1DF1-4EBB-8765-9A99DFA518AD
|
|
p:P9635
|
wd:statement/Q413299-F6343EEA-CFDB-40EA-B26E-4620207A6003
|
|
p:direct-normalized/P2115
|
<http://purl.bioontology.org/ontology/NDFRT/N0000148845>
|
|
p:direct-normalized/P2347
|
<http://www.yso.fi/onto/yso/p39032>
|
|
p:direct-normalized/P4527
|
<http://data.parliament.uk/terms/433902>
|
|
p:direct-normalized/P486
|
<http://id.nlm.nih.gov/mesh/D000068258>
|
|
p:direct-normalized/P592
|
<http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1201583>
|
|
p:direct-normalized/P6366
|
<https://makg.org/entity/2777802072>
|
|
<https://makg.org/entity/2910640057>
|
|
p:direct-normalized/P665
|
<http://www.kegg.jp/entry/D06409>
|
|
p:direct-normalized/P672
|
<http://id.nlm.nih.gov/mesh/D12.776.124.486.485.114.224.060.375>
|
|
<http://id.nlm.nih.gov/mesh/D12.776.124.790.651.114.224.060.438>
|
|
<http://id.nlm.nih.gov/mesh/D12.776.377.715.548.114.224.200.438>
|
|
wdt:P10245
|
"a607001"
|
|
wdt:P10283
|
"C2777802072"
|
|
wdt:P10376
|
"agricultural-and-biological-sciences/bevacizumab"
|
|
"biochemistry-genetics-and-molecular-biology/bevacizumab"
|
|
"immunology-and-microbiology/bevacizumab"
|
|
"medicine-and-dentistry/bevacizumab"
|
|
"nursing-and-health-professions/bevacizumab"
|
|
"pharmacology-toxicology-and-pharmaceutical-science/bevacizumab"
|
|
wdt:P11143
|
"Bevacizumab"
|
|
wdt:P1417
|
"topic/bevacizumab"
|
|
wdt:P2062
|
"8080"
|
|
wdt:P2067
|
149000.0^^xsd:decimal
|
|
wdt:P2115
|
"N0000148845"
|
|
wdt:P2175
|
renal cell carcinoma
|
|
low-grade serous carcinoma
|
|
carcinoid tumor
|
|
melanoma
|
|
macular retinal edema
|
|
gastrointestinal carcinoma
|
|
Kuhnt-Junius degeneration
|
|
peritoneum cancer
|
|
retinal vein occlusion
|
|
neuroendocrine carcinoma
|
|
fallopian tube carcinoma
|
|
rectum adenocarcinoma
|
|
colon cancer
|
|
colon adenocarcinoma
|
|
rectosigmoid cancer
|
|
bronchus carcinoma
|
|
cystoid macular edema
|
|
small intestine carcinoma
|
|
metastatic melanoma
|
|
rectum cancer
|
|
eye disease
|
|
kidney cancer
|
|
non-small-cell lung carcinoma
|
|
anaplastic astrocytoma
|
|
bladder cancer
|
|
exudative vitreoretinopathy 1
|
|
secondary neoplasm
|
|
rare urinary tract tumor
|
|
islet cell carcinoma
|
|
diabetic retinopathy
|
|
brain cancer
|
|
wdt:P2275
|
"bevacizumab"@en
|
|
wdt:P231
|
"216974-75-3"
|
|
wdt:P2347
|
"39032"
|
|
wdt:P267
|
"L01XC07"
|
|
wdt:P274
|
"C₆₆₃₈H₁₀₁₆₀N₁₇₂₀O₂₁₀₈S₄₄"
|
|
wdt:P279
|
chemical compound
|
|
wdt:P2868
|
WHO essential medicines
|
|
monoclonal antibody
|
|
immunological antineoplastic agent
|
|
female reproductive toxicant
|
|
angiogenesis inhibitor
|
|
wdt:P2892
|
"C0796392"
|
|
wdt:P31
|
type of chemical entity
|
|
wdt:P3221
|
"subject/avastin-drug"
|
|
wdt:P3345
|
"253337"
|
|
wdt:P3417
|
"Bevacizumab"
|
|
wdt:P3489
|
US pregnancy category C
|
|
wdt:P366
|
medication
|
|
biopharmaceutical
|
|
wdt:P373
|
"Bevacizumab"
|
|
wdt:P3780
|
Avastin
|
|
wdt:P4235
|
"bevacizumab"
|
|
wdt:P4527
|
"433902"
|
|
wdt:P486
|
"D000068258"
|
|
wdt:P592
|
"CHEMBL1201583"
|
|
wdt:P595
|
"6771"
|
|
wdt:P6366
|
"2777802072"
|
|
"2910640057"
|
|
wdt:P646
|
"/m/0584_3"
|
|
wdt:P652
|
"2S9ZZM9Q9V"
|
|
wdt:P665
|
"D06409"
|
|
wdt:P672
|
"D12.776.124.486.485.114.224.060.375"
|
|
"D12.776.124.790.651.114.224.060.438"
|
|
"D12.776.377.715.548.114.224.200.438"
|
|
wdt:P715
|
"DB00112"
|
|
wdt:P7524
|
"bevacizumab"
|
|
wdt:P9272
|
"55974"
|
|
wdt:P9635
|
"238"
|